Last updated on June 2019

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Brief description of study

This is a Phase 1b, open-label, multicenter study designed to evaluate the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in participants with relapsed/refractory Myelodysplastic Syndromes (MDS).

Clinical Study Identifier: NCT02966782

Find a site near you

Start Over

Yale University /ID# 162544

New Haven, CT United States
  Connect »